Hans H Hirsch
Overview
Explore the profile of Hans H Hirsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
280
Citations
6153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwendinger F, Infanger D, Maurer D, Radtke T, Carrard J, Kropfl J, et al.
SAGE Open Med
. 2025 Feb;
12:20503121241296701.
PMID: 39902344
Background: Patients recovering from COVID-19 often present with impaired health and persisting symptoms such as exercise intolerance ⩾3 months post-infection. Uncertainty remains about long-term recovery. We aimed to review studies...
2.
Cioni M, Muscianisi S, De Cicco M, Basso S, Hirsch H, Fontana I, et al.
Microorganisms
. 2025 Jan;
13(1).
PMID: 39858816
Polyomavirus BK (BKPyV)-associated nephropathy (BKPyV-nephropathy) remains a significant cause of premature kidney allograft failure. In the absence of effective antiviral treatments, current therapeutic approaches rely on immunosuppression (IS) reduction, possibly...
3.
Hirsch H
Kidney Int
. 2025 Jan;
107(2):230-233.
PMID: 39848745
BK polyomavirus remains a vexing issue in kidney transplantation. There are no antiviral drugs, and solely reducing immunosuppression is recommended for management. However, evidence from randomized controlled studies lacks defining...
4.
Hillenbrand C, Akbari Bani D, Follonier O, Kaur A, Weissbach F, Wernli M, et al.
Am J Transplant
. 2024 Nov;
PMID: 39580075
BK polyomavirus (BKPyV) causes premature renal failure in 10% to 30% of kidney transplant recipients (KTRs). Current guidelines recommend screening for new-onset BKPyV-DNAemia/nephropathy and reducing immunosuppression to regain BKPyV-specific immune...
5.
Tepekule B, Jorimann L, Schenkel C, Opitz L, Tschumi J, Wolfensberger R, et al.
iScience
. 2024 Nov;
27(11):111228.
PMID: 39555417
In people with HIV-1 (PWH), (MTB) infection poses a significant threat. While active tuberculosis (TB) accelerates immunodeficiency, the interaction between MTB and HIV-1 during asymptomatic phases remains unclear. Analysis of...
6.
7.
Ingebrigtsen S, Myrmel K, Henriksen S, Wikran G, Herder M, Tylden G, et al.
BMC Neurol
. 2024 Nov;
24(1):436.
PMID: 39521972
Background: Progressive multifocal leukoencephalopathy (PML) is a severe opportunistic brain disease caused by lytic JC polyomavirus (JCPyV) replication in oligodendrocytes. Although JCPyV infection is common in the general population, PML...
8.
Weissbach F, Follonier O, Schmid S, Leuzinger K, Schmid M, Hirsch H
J Virol
. 2024 Nov;
98(12):e0138224.
PMID: 39513696
BK polyomavirus (BKPyV) contributes to premature renal failure in 10%-20% of kidney transplant recipients. Current treatment relies on reducing immunosuppression to regain BKPyV-specific immune control. Subsequently, declining allograft function may...
9.
Kusejko K, Kouyos R, Bernasconi E, Boggian K, Braun D, Calmy A, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1143.
PMID: 39394577
Background: Since the implementation of universal antiretroviral therapy, kidney transplantation (K-Tx) has become a valuable option for treatment of end-stage kidney disease for people with HIV (PWH) with similar patient...
10.
Fichtner A, Schmidt J, Susal C, Carraro A, Oh J, Zirngibl M, et al.
Pediatr Nephrol
. 2024 Oct;
40(3):835-848.
PMID: 39392493
Background: In kidney transplant recipients (KTR), BK polyomavirus-associated nephropathy (BKPyVAN) is a major cause of graft loss. To facilitate the clearance of BKPyV-DNAemia, reduction of immunosuppression is currently the treatment...